Testing the biological embedding hypothesis: Is early life adversity associated with a later proinflammatory phenotype?
Accumulating evidence suggests that the experience of early life adversity is a risk factor for a range of poor outcomes across development, including poor physical health in adulthood. The biological embedding model of early adversity (Miller, Chen, & Parker, 2011) suggests that early adversity might become embedded within immune cells known as monocytes/macrophages, programming them to be overly aggressive to environmental stimuli and insensitive to inhibitory signals, creating a "proinflammatory phenotype" that increases vulnerability to chronic diseases across the life span. We tested this hypothesis in the present study. Adolescent girls (n = 147) had blood drawn every 6 months across a 2.5-year period. To assess inflammatory responses to challenge, their monocytes were stimulated in vitro with a bacterial product, and production of the cytokine interleukin-6 was quantified. Hydrocortisone was added to cultures to assess the cells' sensitivity to glucocorticoids' anti-inflammatory signal. Using cluster analyses, we found that early life adversity was associated with greater odds of displaying a proinflammatory phenotype characterized by relatively larger interleukin-6 responses and relatively less sensitivity to glucocorticoids. In contrast, ongoing social stress was not associated with increasing odds of being categorized in the proinflammatory cluster. These findings suggest that early life adversity increases the probability of developing a proinflammatory phenotype, which, if sustained, could forecast risk for health problems later in life.
University of Georgia.
Katherine B
KB
Ehrlich
University of California at Los Angeles.
Kharah M
KM
Ross
Northwestern University.
Edith
E
Chen
Northwestern University.
Gregory E
GE
Miller
D000293:Adolescent; D044127:Epigenesis, Genetic / Q000235:genetics*; D005260:Female; D006801:Humans; D006854:Hydrocortisone; D007249:Inflammation / Q000235:genetics* / Q000276:immunology; D015850:Interleukin-6 / Q000097:blood*; D008016:Life Change Events; D010641:Phenotype; D011336:Probability; D012307:Risk Factors; D013315:Stress, Psychological / Q000150:complications* / Q000235:genetics*
C508600:IL6 protein, human; D015850:Interleukin-6; D006854:Hydrocortisone
Prog Brain Res. 2010;181:43-53
20478432
Psychol Bull. 2014 May;140(3):774-815
24417575
PLoS One. 2012;7(6):e38669
22685596
Psychol Sci. 2015 Feb;26(2):111-21
25564524
Biol Psychiatry. 2016 Jul 1;80(1):23-32
26166230
J Abnorm Psychol. 1991 Nov;100(4):555-61
1757669
Circulation. 2003 Jan 28;107(3):370-1
12551854
J Pathol. 2008 Jan;214(2):161-78
18161744
Biol Psychiatry. 2012 Jul 1;72(1):34-40
22494534
J Pediatr Nurs. 2009 Oct;24(5):378-88
19782896
Nature. 2006 Dec 14;444(7121):860-7
17167474
Child Dev. 1992 Feb;63(1):103-15
1551320
Psychol Med. 1997 Sep;27(5):1101-19
9300515
Annu Rev Neurosci. 2001;24:1161-92
11520931
Circulation. 2005 Jun 28;111(25):3481-8
15983262
Annu Rev Psychol. 2009;60:549-76
18652544
Child Dev. 2004 Jul-Aug;75(4):1039-52
15260863
Trends Endocrinol Metab. 2013 Mar;24(3):109-19
23312823
Psychol Bull. 2011 Nov;137(6):959-97
21787044
Br J Psychiatry. 2010 Nov;197(5):378-85
21037215
Child Dev. 1994 Apr;65(2 Spec No):649-65
8013245
J Pers. 2011 Feb;79(1):2-50
21223263
JAMA. 1998 May 13;279(18):1477-82
9600484
Child Dev Perspect. 2013 Jun 1;7(2):67-73
24032051
Lancet. 2002 Nov 23;360(9346):1640-5
12457787
BMJ. 2000 Apr 1;320(7239):898-902
10741994
Am J Psychiatry. 2003 Sep;160(9):1554-65
12944327
J Child Psychol Psychiatry. 2005 Mar;46(3):235-45
15755300
Psychosom Med. 2016 Jan;78(1):91-101
26727383
Dev Psychopathol. 2011 Aug;23(3):921-38
21756442
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14716-21
19617551
J Am Coll Cardiol. 2009 Dec 1;54(23):2129-38
19942084
Dev Psychopathol. 2016 Feb;28(1):127-38
25851449
Ann N Y Acad Sci. 1999;896:30-47
10681886
Psychosom Med. 2009 Jan;71(1):57-62
19073750
Child Dev. 1992 Dec;63(6):1321-35
1446555
Child Dev. 1999 May-Jun;70(3):660-77
10368914
Annu Rev Public Health. 2005;26:1-35
15760279
Nat Rev Neurosci. 2009 Jun;10(6):434-45
19401723
Psychol Bull. 2007 Jan;133(1):25-45
17201569
Ann N Y Acad Sci. 2009 Oct;1179:1-18
19906229
Clin Psychol Sci. 2013 Jan;1(1):30-40
23638342
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11287-92
25049403
Cell. 2010 Mar 19;140(6):871-82
20303877
Nutr Rev. 2007 Dec;65(12 Pt 2):S253-9
18240558
Lancet. 2010 Jan 9;375(9709):132-40
20031199
Neurosci Biobehav Rev. 2010 Sep;35(1):33-8
19751761
Psychopharmacology (Berl). 2011 Mar;214(1):89-106
20949351
Psychosom Med. 2014 Jul-Aug;76(6):460-7
24979577
Psychosom Med. 2009 Apr;71(3):329-33
19196810
Pediatr Res. 2011 May;69(5 Pt 2):26R-33R
21289540
Am Psychol. 2012 May-Jun;67(4):309-18
22390355
BMJ. 1990 Nov 17;301(6761):1111
2252919
Ann N Y Acad Sci. 1999;896:85-95
10681890
Annu Rev Psychol. 2006;57:255-84
16318596
Biol Psychiatry. 2008 Aug 15;64(4):266-72
18440494
JAMA. 2009 Jun 3;301(21):2252-9
19491187
Dev Psychol. 2009 Jul;45(4):1195-9
19586189
Pediatrics. 2012 Jan;129(1):e232-46
22201156
Neurosci Biobehav Rev. 2005;29(4-5):843-65
15893378
Psychol Bull. 2002 Mar;128(2):330-66
11931522
J Clin Child Adolesc Psychol. 2006 Feb;35(1):103-15
16390306